Cargando…

Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy

The ability to predict complete pathologic response or sensitivity to radiation before treatment would have a significant impact on the selection of patients for preoperative radiotherapy or chemo-radiation therapy schedules. The aim of this study was to determine the value of epidermal growth facto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zlobec, I, Vuong, T, Compton, C C, Lugli, A, Michel, R P, Hayashi, S, Jass, J R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361457/ https://www.ncbi.nlm.nih.gov/pubmed/18182986 http://dx.doi.org/10.1038/sj.bjc.6604172

Ejemplares similares

A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy
por: Zlobec, I, et al.
Publicado: (2007)

Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients
por: Zlobec, I, et al.
Publicado: (2014)

Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy
por: Negri, F V, et al.
Publicado: (2008)

Two-marker protein profile predicts poor prognosis in patients with early rectal cancer
por: Zlobec, I, et al.
Publicado: (2008)

Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer
por: Galván, J A, et al.
Publicado: (2015)

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer
por: Lugli, A, et al.
Publicado: (2009)

VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo
por: Rennel, E S, et al.
Publicado: (2009)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

AEG-1 expression is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy: a study in a Swedish clinical trial
por: Gnosa, S, et al.
Publicado: (2014)

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression
por: Couvelard, A, et al.
Publicado: (2005)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours
por: Salto-Tellez, M, et al.
Publicado: (2007)

Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?
por: Karayan-Tapon, L, et al.
Publicado: (2008)

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
por: Paliga, A, et al.
Publicado: (2012)

Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer
por: Koelzer, V H, et al.
Publicado: (2013)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer
por: Rogers, A C, et al.
Publicado: (2016)

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
por: Kut, C, et al.
Publicado: (2007)

Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma
por: Pritchard-Jones, R O, et al.
Publicado: (2007)

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
por: Patard, J-J, et al.
Publicado: (2009)

The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer
por: Patel, Meera, et al.
Publicado: (2018)

HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium
por: Kurosu, T, et al.
Publicado: (2011)

A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells
por: Barr, M P, et al.
Publicado: (2005)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
por: Lugli, A, et al.
Publicado: (2010)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB–IIA of cervical cancer
por: Beskow, C, et al.
Publicado: (2006)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
por: Gavalas, N G, et al.
Publicado: (2012)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
por: Kimura, H, et al.
Publicado: (2006)

Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours
por: Caiazza, F, et al.
Publicado: (2011)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
por: Rao, S R, et al.
Publicado: (2017)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation
por: Rahman, M M, et al.
Publicado: (2009)

Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
por: Balermpas, P, et al.
Publicado: (2014)

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways
por: Nabeshima, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nbvplm9a6r8po5h961dsi3j6n1